keyword
MENU ▼
Read by QxMD icon Read
search

Inflammatory bowel disease, tnf, adalimumab

keyword
https://www.readbyqxmd.com/read/29771301/anti-tnf-levels-in-cord-blood-at-birth-are-associated-with-anti-tnf-type
#1
Shannon L Kanis, Alison de Lima, Cokkie van der Ent, Dimitris Rizopoulos, C Janneke van der Woude
Background and Aims: Pregnancy guidelines for women with Inflammatory Bowel Disease (IBD) provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit fetal exposure. Although infliximab (IFX) leads to higher anti-TNF concentrations in cord blood than adalimumab (ADA), recommendations are similar. We aimed to demonstrate the effect of anti-TNF cessation during pregnancy on fetal exposure, for IFX and ADA separately. Methods: We conducted a prospective single center cohort study...
May 15, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29766731/-current-and-prospective-biologics-and-small-molecules-in-the-treatment-of-inflammatory-bowel-diseases
#2
Milan Buc
Crohns disease (CD) and ulcerative colitis (UC) belong to chronic inflammatory bowel diseases, which are induced by autoimmune processes. While CD is characterized by over-activity of Th1, ILC1, and MAIT cells, UC is mediated by exaggerated activities of Th2 and ILC2 cells and cytokines they produce. Knowledge of the pathogenesis enabled a rational therapy based mostly on biologics and small molecules. TNF is the principal proinflammatory cytokine in both diseases. Anti-TNF monoclonal antibodies, mostly infliximab or adalimumab were therefore introduced to their treatment...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29752913/development-and-validation-of-a-targeted-affinity-enrichment-and-lc-ms-ms-proteomics-approach-for-the-therapeutic-monitoring-of-adalimumab
#3
Yifei Yang, Emily Wysocki, Kwasi Antwi, Eric Niederkofler, Edward K Y Leung, Eszter Lazar-Molnar, Kiang-Teck J Yeo
BACKGROUND: The anti-tumor necrosis factor alpha (TNFα) therapeutic monoclonal antibodies (mAbs), such as adalimumab, are widely used in the treatment of rheumatoid arthritis, inflammatory bowel diseases, and other auto-immune diseases. The administration of adalimumab can elicit the immune responses from the patients, resulting in the formation of anti-drug antibodies (ADAbs). The ADAbs can diminish the therapeutic effects of adalimumab by neutralizing the TNFα binding site or increase its clearance from circulation...
May 9, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29736839/stricturing-and-fistulizing-crohn-s-disease-is-associated-with-anti-tumor-necrosis-factor-induced-psoriasis-in-patients-with-inflammatory-bowel-disease
#4
Adam V Weizman, Robyn Sharma, N M Afzal, Wei Xu, Scott Walsh, Joanne M Stempak, Geoffrey C Nguyen, Ken Croitoru, A Hillary Steinhart, Mark S Silverberg
BACKGROUND: Paradoxical development of psoriasis in patients on anti-TNF agents has been increasingly reported. AIM: The aim was to characterize the prevalence and clinical characteristics of anti-TNF-associated psoriasis in a large cohort of inflammatory bowel disease patients. METHODS: Medical records of patients with Crohn's disease or ulcerative colitis treated with anti-TNF therapy at a single, tertiary IBD center were identified between 2004 and 2016...
May 8, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29718343/dermatological-manifestations-in-pediatric-patients-with-inflammatory-bowel-diseases-on-anti-tnf-therapy
#5
Shilpa Sridhar, Ross M Maltz, Brendan Boyle, Sandra C Kim
Background: Anti-tumor necrosis factor (anti-TNF) therapies are effective treatments for inflammatory bowel diseases (IBD). However, infections, psoriasis, and eczema are potential manifestations. Descriptions of these are limited. Our aim was to characterize these skin manifestations in children with IBD on anti-TNF therapy. Methods: Our study is a retrospective review of IBD patients ranging in age from 6 to 18 years who were treated with anti-TNFs from 2010-2015...
April 27, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29697550/use-of-infliximab-biosimilar-versus-originator-in-a-paediatric-united-kingdom-inflammatory-bowel-disease-induction-cohort
#6
Neil Chanchlani, Kajal Mortier, Linda J Williams, Rafeeq Muhammed, Marcus K H Auth, Mike Cosgrove, Andrew Fagbemi, John Fell, Sonny Chong, Veena Zamvar, Warren Hyer, W Michael Bisset, Mary-Anne Morris, Astor Rodrigues, Sally G Mitton, Su Bunn, R Mark Beattie, Anne Willmott, David C Wilson, Richard K Russell
OBJECTIVES: To summarize short-term effectiveness, safety, and cost of using infliximab biosimilar (IFX-B) drugs, (Inflectra™ and Remsima™) compared to originator infliximab (IFX-O) (Remicade®) in biologic naive pediatric inflammatory bowel disease in the United Kingdom. METHODS: Prospective audit of patients starting anti-TNF therapy. Disease severity, response to treatment, and remission rate was measured by Pediatric Crohn's Disease Activity Index (PCDAI) and/or Physician Global Assessment (PGA)...
April 23, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29655972/effectiveness-and-safety-of-anti-tnf-therapy-for-inflammatory-bowel-disease-in-liver-transplant-recipients-for-primary-sclerosing-cholangitis-a-nationwide-case-series
#7
Romain Altwegg, Roman Combes, David Laharie, Victor De Ledinghen, Sylvie Radenne, Filomena Conti, Olivier Chazouilleres, Christophe Duvoux, Jérôme Dumortier, Vincent Leroy, Xavier Treton, François Durand, Sébastien Dharancy, Maria Nachury, Félix Goutorbe, Géraldine Lamblin, Lucile Boivineau, Laurent Peyrin-Biroulet, Georges-Philippe Pageaux
BACKGROUND: There is a lack of consensus regarding the treatment of inflammatory bowel disease (IBD) after liver transplantation (LT) forprimary sclerosing cholangitis (PSC). AIM: To investigate the safety and effectiveness of anti-TNF therapy in patients with IBD after a LT for PSC. METHODS: We reviewed the medical files of all of the IBD patients who underwent a LT for PSC and who were treated with anti-TNF therapy at 23 French liver transplantation centers between 1989 and 2012...
March 13, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29623105/subtherapeutic-concentrations-of-infliximab-and-adalimumab-are-associated-with-increased-disease-activity-in-crohn-s-disease
#8
Arne Carlsen, Roald Omdal, Kristian Øgreid Leitao, Kjetil Isaksen, Anne Kristine Hetta, Lars Normann Karlsen, Lars Aabakken, Nils Bolstad, David Warren, Knut E A Lundin, Tore Grimstad
Background: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic drug concentrations were associated with increased levels of disease activity. Methods: In a single-center cross-sectional study, we included patients with ulcerative colitis or Crohn's disease who were receiving infliximab or adalimumab maintenance therapy...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29518097/anti-tnf%C3%AE-therapy-in-ibd-alters-brain-activity-reflecting-visceral-sensory-function-and-cognitive-affective-biases
#9
Marcus A Gray, Che-Yung Chao, Heidi M Staudacher, Natasha A Kolosky, Nicholas J Talley, Gerald Holtmann
BACKGROUND: In inflammatory bowel disease (IBD), immune activation with increased circulating TNF-α is linked to the intensity of gastrointestinal symptoms and depression or anxiety. A central feature of depression is cognitive biases linked to negative attributions about self, the world and the future. We aimed to assess the effects of anti-TNFα therapy on the central processing of self-attribution biases and visceral afferent information in patients with Crohn's disease. METHODS: We examined 9 patients with Crohn's disease (age 26...
2018: PloS One
https://www.readbyqxmd.com/read/29492747/biosimilars-in-the-treatment-of-inflammatory-bowel-disease-supporting-evidence-in-2017
#10
REVIEW
Frank I Scott, Gary R Lichtenstein
PURPOSE OF REVIEW: Monoclonal antibodies targeting tumor necrosis factor-alpha, integrin molecules, and interleukin-12/23 have become backbone therapies for Crohn's disease and ulcerative colitis. While clinically effective, these biologic therapies come with significant expense, contributing to overall healthcare spending in the USA. Biosimilars have the potential to significantly reduce expenditures secondary to the use of biologic medications such as infliximab and adalimumab, though their complicated manufacturing process results in inherent differences in structure when compared to the originator compounds...
March 2018: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/29440933/population-based-cohort-study-on-comparative-effectiveness-and-safety-of-biologics-in-inflammatory-bowel-disease
#11
Riccardo Di Domenicantonio, Francesco Trotta, Silvia Cascini, Nera Agabiti, Anna Kohn, Antonio Gasbarrini, Marina Davoli, Antonio Addis
Background: The comparison of effectiveness and safety of anti-tumor necrosis factor-alpha agents for the treatment of inflammatory bowel disease (IBD) is relevant for clinical practice and stakeholders. Objective: The objective of this study was to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn's disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). Methods: A retrospective population-based cohort study was performed using health information systems data from Lazio region, Italy...
2018: Clinical Epidemiology
https://www.readbyqxmd.com/read/29379609/protocol-for-a-multicentred-randomised-controlled-trial-investigating-the-use-of-personalised-golimumab-dosing-tailored-to-inflammatory-load-in-ulcerative-colitis-the-goal-arc-study-glm-dose-optimisation-to-adequate-levels-to-achieve-response-in-colitis-led
#12
Juliette Sheridan, Carol Ann Coe, Peter Doran, Laurence Egan, Garret Cullen, David Kevans, Jan Leyden, Marie Galligan, Aoibhlinn O'Toole, Jane McCarthy, Glen Doherty
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), often leading to an impaired quality of life in affected patients. Current treatment modalities include antitumour necrosis factor (anti-TNF) monoclonal antibodies (mABs) including infliximab, adalimumab and golimumab (GLM). Several recent retrospective and prospective studies have demonstrated that fixed dosing schedules of anti-TNF agents often fails to consistently achieve adequate circulating therapeutic drug levels (DL) with consequent risk of immunogenicity treatment failure and potential risk of hospitalisation and colectomy in patients with UC...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29363355/biologic-induced-infections-in-inflammatory-bowel-disease-the-tnf-%C3%AE-antagonists
#13
Sean M McConachie, Sheila M Wilhelm, Ashish Bhargava, Pramodini B Kale-Pradhan
OBJECTIVE: To review the mechanism and association of infectious risk among the tumor-necrosis factor α (TNF-α) antagonists used in inflammatory bowel disease. DATA SOURCES: A PubMed literature search was performed using the following search terms: infliximab, adalimumab, certolizumab, golimumab, inflammatory bowel disease, crohn's, ulcerative colitis, adverse effects, adverse events, safety, and infection. STUDY SELECTION AND DATA EXTRACTION: Meta-analyses and cohort studies with outcomes pertaining to quantitative infectious risk were reviewed...
January 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29361083/antibody-response-to-hepatitis-b-virus-vaccine-is-impaired-in-patients-with-inflammatory-bowel-disease-on-infliximab-therapy
#14
Perry K Pratt, Nunes David, Horst C Weber, Frédéric F Little, Themistoklis Kourkoumpetis, Gregory J Patts, Janice Weinberg, Francis A Farraye
Background: Studies have demonstrated an association between anti-TNF/immunomodulator agents used in inflammatory bowel disease (IBD) and impaired hepatitis B virus (HBV) vaccine immunogenicity, but little data exist on whether specific medication types affect protective HBsAb titers. Our aim was to analyze this association. Methods: This is a retrospective cohort study. Inclusion criteria: age ≥18, diagnosis of Crohn's disease (CD) or ulcerative colitis (UC), previous HBV vaccination series and/or ≥1 positive HBsAb, and record of IBD therapy in 6 months before titer level...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29356768/real-life-anti-tumor-necrosis-factor-experience-in-more-than-500-patients-high-co-immunosuppression-rates-but-low-rates-of-quantifying-treatment-response
#15
Victoria M Merrick, Kajal Mortier, Linda J Williams, Rafeeq Muhammed, Marcus K H Auth, Mamoun Elawad, John M E Fell, R Mark Beattie, Sabarinathan Loganathan, Franco Torrente, Mary-Anne Morris, Charles Charlton, Nick M Croft, Astor Rodrigues, Mark Furman, Babu Vadamalayan, Huw Jenkins, Veena Zamvar, Sally G Mitton, Sonny Chong, Mike Cosgrove, Anthony Akobeng, David C Wilson, Richard K Russell
OBJECTIVE: The aim of this study was to measure the effectiveness, safety, and use of anti-tumor necrosis Factor (TNF) therapy in pediatric inflammatory bowel disease in the United Kingdom (UK). METHODS: Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment +/or the Paediatric Crohn Disease Activity Index. RESULTS: A total of 37 centers participated (23/25 specialist pediatric inflammatory bowel disease sites)...
February 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29349693/anti-tumor-necrosis-factor-%C3%AE-induced-dermatological-complications-in-a-large-cohort-of-inflammatory-bowel-disease-patients
#16
P Andrade, S Lopes, R Gaspar, A Nunes, S Magina, G Macedo
BACKGROUND/AIMS: The broader use of anti-tumor necrosis factor (TNF) agents in inflammatory bowel disease (IBD) has been associated with a high rate of adverse reactions. Dermatological complications are among the most common adverse events. We assessed the incidence, risk factors, management, and outcome of anti-TNF-induced dermatological complications in a large cohort of IBD patients. METHODS: This was an observational retrospective study at a single tertiary referral center...
March 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29333082/a-fcgr3a-polymorphism-predicts-anti-drug-antibodies-in-chronic-inflammatory-bowel-disease-patients-treated-with-anti-tnf
#17
Patricia Romero-Cara, Daniel Torres-Moreno, José Pedregosa, Juan Antonio Vílchez, María Sergia García-Simón, Guadalupe Ruiz-Merino, Senador Morán-Sanchez, Pablo Conesa-Zamora
BACKGROUND: The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance...
2018: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29224199/paradoxical-psoriasiform-reactions-of-anti-tumour-necrosis-factor-therapy-in-inflammatory-bowel-disease-patients
#18
Faseeha C Peer, Andrew Miller, Paul Pavli, Kavitha Subramaniam
Anti-tumour necrosis factor (TNF) agents have demonstrated efficacy in inflammatory bowel disease (IBD). Cutaneous reactions such as new onset psoriasis or psoriasiform-like reactions are among the most common adverse reactions. We retrospectively identified cases of anti-TNF-induced psoriasis or psoriasiform manifestations in IBD patients at a tertiary centre in Australia. A total of 10 (six females) of 270 (3.7%) IBD patients treated with anti-TNF therapy developed drug-induced psoriatic or psoriasiform-like reactions: five patients were treated with infliximab and five with adalimumab; nine had Crohn disease...
December 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29214394/serious-adverse-events-associated-with-anti-tumor-necrosis-factor-alpha-agents-in-pediatric-onset-inflammatory-bowel-disease-and-juvenile-idiopathic-arthritis-in-a-real-life-setting
#19
Serena Pastore, Samuele Naviglio, Arianna Canuto, Loredana Lepore, Stefano Martelossi, Alessandro Ventura, Andrea Taddio
OBJECTIVES: Anti-tumor necrosis factor alpha (anti-TNF-α) agents are generally well tolerated, yet they can be associated with serious adverse events (SAEs) in a minority of patients. We examined the incidence of SAEs in a pediatric referral center for chronic rheumatologic and gastroenterological inflammatory disorders. METHODS: Retrospective analysis of SAEs occurring during treatment with anti-TNF-α agents in patients with juvenile idiopathic arthritis (JIA) (n = 78)  or pediatric-onset inflammatory bowel disease (IBD) (n = 105) seen at the Institute for Maternal and Child Health IRCCS "Burlo Garofolo" in Trieste, Italy, between June 2001 and February 2016...
December 6, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29093622/adalimumab-efficacy-in-enteropathic-spondyloarthritis-a-12-mo-observational-multidisciplinary-study
#20
Michele Maria Luchetti, Devis Benfaremo, Francesco Ciccia, Laura Bolognini, Monia Ciferri, Alessia Farinelli, Matteo Rossini, Piergiorgio Mosca, Giovanni Triolo, Armando Gabrielli
AIM: To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS: A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires...
October 21, 2017: World Journal of Gastroenterology: WJG
keyword
keyword
24901
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"